Keryx Biopharmaceuticals (KERX) Pressure on Script Data Creates a Buying Chance - Cowen
Tweet Send to a Friend
Cowen analyst Boris Peaker reiterated an Outperform rating and $25 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) saying the panic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
